• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk diabetes drug succeeds in late-stage trial

August 17, 2017 By Sarah Faulkner

Novo NordiskShares in Novo Nordisk (NYSE:NVO) rose nearly 5% yesterday afternoon after the insulin-maker said that its once-weekly diabetes drug, semaglutide, succeeded in lowering glucose levels in a late-stage trial.

The 40-week trial enrolled 1,200 patients and evaluated two dosages of semaglutide in combination with a standard-of-care-drug. The study compared its drug against Eli Lilly‘s (NYSE:LLY) dulaglutide compound.

Nordisk reported that semaglutide was statistically significant in lowering glucose levels and body weight in patients with Type II diabetes compared to dulaglutide.

The company also noted that the number of patients reporting cases of diabetic retinopathy was low and comparable in both treatment arms.

“The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire Sustain program” EVP and chief science officer Mads Krogsgaard Thomsen said in prepared remarks. “We are excited about the potential of semaglutide to set a new standard for treatment of Type II diabetes.”

Semaglutide and Eli Lilly’s dulglutide are both GLP-1 analogues – drugs that trigger the production of insulin, while lessening appetite and food intake. Lilly’s Trulicity product has been a primary growth driver for the drugmaker, but analysts have suggested that Nordisk’s semaglutide could represent competition.

“While we project that Lilly will retain its leadership position in the once-weekly segment, Novo has made headway with its oral formulation that could potentially shift the market dynamics in its favor over the longer term,” Barclays analysts said, according to Reuters.

Earlier in August, Nordisk posted Street-beating second quarter results, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures.

Last year, the Danish company saw shares drop more than 40% after it slashed its long-term operating profit forecasts, citing price pressures in the U.S. market. This year, Nordisk raised its full-year sales growth forecast in local currencies from o% – 3% to 1% – 3%.

Nordisk posted an operating profit of 13.4 billion crowns ($2.1 billion) in the second quarter, topping estimates.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co., Novo Nordisk

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS